−1.28SEK
−326.90 MSEK
57.60 MSEK
159.42 M
About EGETIS THERAPEUTICS AB
Sector
CEO
Nicklas Westerholm
Headquarters
Stockholm
Website
Employees (FY)
29
Founded
2006
ISIN
SE0003815604
FIGI
BBG001K77XP2
Egetis Therapeutics AB is an innovative and integrated pharmaceutical company, which engages in the development of new drugs for treatment of serious diseases. Its projects include Emcitate for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency. The company was founded by Torsten Almén, Heidi Brurok, Louis J. Ignarro, Per Jynge, Jan Olof Gustav Karlsson, Ingemar Lundström, and Rob Towart in 2006 and is headquartered in Stockholm, Sweden.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of EGTX is 6.27 SEK — it has increased by 0.16% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange EGETIS THERAPEUTICS AB stocks are traded under the ticker EGTX.
EGETIS THERAPEUTICS AB is going to release the next earnings report on May 3, 2024. Keep track of upcoming events with our Earnings Calendar.
EGTX stock is 2.74% volatile and has beta coefficient of 1.05. Check out the list of the most volatile stocks — is EGETIS THERAPEUTICS AB there?
EGTX earnings for the last quarter are −0.35 SEK per share, whereas the estimation was −0.26 SEK resulting in a −32.08% surprise. The estimated earnings for the next quarter are −0.35 SEK per share. See more details about EGETIS THERAPEUTICS AB earnings.
EGETIS THERAPEUTICS AB revenue for the last quarter amounts to 12.20 M SEK despite the estimated figure of 5.25 M SEK. In the next quarter revenue is expected to reach 8.35 M SEK.
Yes, you can track EGETIS THERAPEUTICS AB financials in yearly and quarterly reports right on TradingView.
EGTX stock has risen by 7.18% compared to the previous week, the month change is a 5.00% fall, over the last year EGETIS THERAPEUTICS AB has showed a 25.45% decrease.
EGTX net income for the last quarter is −86.30 M SEK, while the quarter before that showed −86.20 M SEK of net income which accounts for −0.12% change. Track more EGETIS THERAPEUTICS AB financial stats to get the full picture.
Today EGETIS THERAPEUTICS AB has the market capitalization of 1.83 B, it has decreased by 9.63% over the last week.
No, EGTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, EGTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EGETIS THERAPEUTICS AB stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 29.00 employees. See our rating of the largest employees — is EGETIS THERAPEUTICS AB on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So EGETIS THERAPEUTICS AB technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating EGETIS THERAPEUTICS AB stock shows the buy signal. See more of EGETIS THERAPEUTICS AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on EGETIS THERAPEUTICS AB future price: according to them, EGTX price has a max estimate of 17.70 SEK and a min estimate of 11.00 SEK. Read a more detailed EGETIS THERAPEUTICS AB forecast: see what analysts think of EGETIS THERAPEUTICS AB and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. EGETIS THERAPEUTICS AB EBITDA is −316.70 M SEK, and current EBITDA margin is −549.83%. See more stats in EGETIS THERAPEUTICS AB financial statements.